Extended-Release Memantine

Phase 1

Extended-Release Memantine is one of 6 therapeutic programs targeting Major Depressive Disorder (MDD). It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Major Depressive Disorder (MDD)Recruiting

Major Depressive Disorder (MDD)Phase 1

Recruiting

Competition

Competitive Landscape

10 competitors in Major Depressive Disorder (MDD)

#DrugCompanyPhaseTrials

ONO-1110

Ono Pharmaceutical Co. Ltd

Phase 2

1 2

CYB003

CCybin IRL Limited

Phase 3

1 3

SPT-300

SSeaport Therapeutics

Phase 2

2 4

ACP-211

AACADIA Pharmaceuticals Inc.

Phase 2

1 5

CLE-100

CClexio Biosciences Ltd.

Phase 2

1 6

Extended-Release Memantine

JJeffrey Miller

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Major Depressive Disorder (MDD)

NCT07139834

Clinical

Trials by Indication[1]

Major Depressive Disorder (MDD)1 trial

Examining the Effects of Escitalopram and Memantine on Pattern Separation in Major Depressive Disorder

Recruiting·JJeffrey Miller·Phase 1·NCT07139834·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Extended-Release Memantine. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Extended-Release Memantine. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Jeffrey Miller company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: JJeffrey Miller

Extended-Release Memantine

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Major Depressive Disorder (MDD)1 trial

References

Drug Info

Quick Facts

Related News